Cancer Family
Malignant Digestive System Neoplasm
CI-CAN-00000229Explore in graph →
4,262 active trials43 approved drugs556 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000229Explore in graph →
Clinical trials
19,101 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2,000)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05111626 | Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.(FORTITUDE-102) | terminated | Phase 3 | 515 | AmgenINDUSTRY | 29 | Sep 10, 2026 | clinicaltrials |
| NCT04246177 | Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012) | terminated | Phase 3 | 480 | Merck Sharp & Dohme LLC |
| 27 |
| Sep 3, 2026 |
| clinicaltrials |
| NCT04949256 | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014). | terminated | Phase 3 | 863 | Merck Sharp & Dohme LLCINDUSTRY | 25 | Aug 21, 2026 | clinicaltrials |
| NCT03656536 | A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma(FIGHT-302) | terminated | Phase 3 | 167 | Incyte CorporationINDUSTRY | 19 | Aug 11, 2026 | clinicaltrials |
| NCT07152821 | Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma(BATTMAN) | terminated | Phase 3 | 21 | Canadian Cancer Trials GroupNETWORK | 1 | Jul 16, 2026 | clinicaltrials |
| NCT02200042 | Radiation Therapy vs. Observation Following Gemcitabine and Cisplatin for Inoperable Localized Liver Cancer | terminated | Phase 3 | 1 | NRG OncologyOTHER | 2 | Jul 13, 2026 | clinicaltrials |
| NCT03426371 | Epidermal Growth Factor Receptor (EGFR) Antagonist Chimeric Anti-EGFR Monoclonal Antibody Trial | terminated | Phase 3 | 52 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 12, 2026 | clinicaltrials |
| NCT05131776 | EUS-guided Intra-tumour Injection of OncoSil for Locally Advanced Pancreatic Carcinoma. | terminated | Phase 2 / Phase 3 | 2 | Chinese University of Hong KongOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT04777851 | Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7(REPLACE) | terminated | Phase 3 | 45 | Translational Research in OncologyOTHER | 13 | Mar 9, 2026 | clinicaltrials |
| NCT03042169 | Surgical Resection Plus Chemotherapy Versus Chemotherapy Alone in Oligometastatic Stage IV Gastric Cancer(SURGIGAST) | terminated | Phase 3 | 6 | University Hospital, LilleOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT05171166 | Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial. | terminated | Phase 2 / Phase 3 | 18 | Peking UniversityOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT04856787 | A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRC | terminated | Phase 2 / Phase 3 | 62 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | May 18, 2025 | clinicaltrials |
| NCT02467582 | Adjuvant Aspirin Treatment for Colon Cancer Patients | terminated | Phase 3 | 1,040 | Swiss Cancer InstituteOTHER | 4 | May 16, 2025 | clinicaltrials |
| NCT02807181 | SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma(SIRCCA) | terminated | Phase 2 / Phase 3 | 89 | Sirtex MedicalINDUSTRY | 8 | May 9, 2025 | clinicaltrials |
| NCT04316013 | Volatile Anaesthesia and Perioperative Outcomes Related to Cancer: the VAPOR-C Trial | terminated | Phase 3 | 254 | Peter MacCallum Cancer Centre, AustraliaOTHER | 3 | Mar 14, 2025 | clinicaltrials |
| NCT04709380 | Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma With PVTT | terminated | Phase 3 | 36 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 26, 2025 | clinicaltrials |
| NCT01167725 | Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer | terminated | Phase 3 | 340 | Alliance for Clinical Trials in OncologyOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT02867839 | Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric Cancer(RESCUE-GC) | terminated | Phase 3 | 29 | Peking University Cancer Hospital & InstituteOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT03512756 | A Randomized Phase 2/3 Multi-Center Study of SM-88 in Participants With Metastatic Pancreatic Cancer | terminated | Phase 2 / Phase 3 | 130 | Tyme, IncINDUSTRY | 1 | Nov 6, 2024 | clinicaltrials |
| NCT03960008 | Stereotactic Body Radiation Therapy (SBRT) vs Trans-Arterial Chemoembolization (TACE) as Bridge to Transplant(SBRTvsTACE) | terminated | Phase 3 | 9 | Lahey ClinicOTHER | 2 | Aug 28, 2024 | clinicaltrials |
| NCT05223673 | Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer(COLSTAR) | terminated | Phase 3 | 7 | Institut de Recherches Internationales ServierOTHER | 6 | Aug 20, 2024 | clinicaltrials |
| NCT00113256 | Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer | terminated | Phase 2 / Phase 3 | 39 | Astex Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 2, 2024 | clinicaltrials |
| NCT03773302 | Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations | terminated | Phase 3 | 48 | QED Therapeutics, a BridgeBio companyINDUSTRY | 15 | May 8, 2024 | clinicaltrials |
| NCT04300114 | A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy | terminated | Phase 3 | 5 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Mar 28, 2024 | clinicaltrials |
| NCT03500874 | Adjuvant Systemic Chemotherapy With or Without HAI-FUDR in Patients With Resected CRLM | terminated | Phase 3 | 92 | Sun Yat-sen UniversityOTHER | 1 | Jan 22, 2024 | clinicaltrials |
| NCT04592861 | Carbon Ion RT for Locally Advanced Pancreatic Cancer | terminated | Phase 3 | 5 | Albert Einstein College of MedicineOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT04329949 | Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma(RELIANT) | terminated | Phase 3 | 43 | Corcept TherapeuticsINDUSTRY | 1 | Nov 18, 2023 | clinicaltrials |
| NCT04066491 | Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC | terminated | Phase 2 / Phase 3 | 309 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 15 | Nov 14, 2023 | clinicaltrials |
| NCT01011478 | Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery | terminated | Phase 3 | 406 | NSABP Foundation IncNETWORK | 2 | Aug 16, 2023 | clinicaltrials |
| NCT00658593 | Gemcitabine With/Out Capecitabine in Locally Advanced, Unresectable, or Metastatic Biliary Cancer | terminated | Phase 3 | 19 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT00303628 | Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer | terminated | Phase 3 | 355 | ECOG-ACRIN Cancer Research GroupNETWORK | 4 | Jul 6, 2023 | clinicaltrials |
| NCT00002525 | Perioperative Chemotherapy in Treating Patients With Colon Cancer That Can Be Surgically Removed | terminated | Phase 3 | 859 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jun 28, 2023 | clinicaltrials |
| NCT04163900 | Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer | terminated | Phase 3 | 773 | NuCana plcOTHER | 15 | May 24, 2023 | clinicaltrials |
| NCT03678428 | FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM | terminated | Phase 3 | 92 | Sun Yat-sen UniversityOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT03236649 | The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects | terminated | Phase 3 | 89 | Beijing Shenogen Biomedical Co., LtdINDUSTRY | 1 | Feb 8, 2023 | clinicaltrials |
| NCT03827044 | Avelumab Plus 5-FU Based Chemotherapy as Adjuvant Treatment for Stage 3 MSI-High or POLE Mutant Colon Cancer(POLEM) | terminated | Phase 3 | 30 | Royal Marsden NHS Foundation TrustOTHER | 1 | Oct 7, 2022 | clinicaltrials |
| NCT04985136 | A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC) | terminated | Phase 3 | 1 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 1, 2022 | clinicaltrials |
| NCT01402908 | A Phase III PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related HCC After Surgical Resection(PATRON) | terminated | Phase 3 | 520 | Cellxpert Biotechnology Corp.INDUSTRY | 4 | Jun 23, 2022 | clinicaltrials |
| NCT03970694 | Neoadjuvant Chemoradiotherapy Versus Neoadjuvant Chemotherapy For Unresectable Locally Advanced Colon Cancer | terminated | Phase 3 | 49 | Sun Yat-sen UniversityOTHER | 1 | Jun 8, 2022 | clinicaltrials |
| NCT03475680 | Mechanical Bowel Preparation and Oral Antibiotics Before Colon Cancer Surgery(COLONPREP) | terminated | Phase 3 | 193 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 17, 2022 | clinicaltrials |
| NCT02588248 | L-Menthol Injection as a Novel Technique During Colonoscopy(MINT-C) | terminated | Phase 3 | 82 | University Hospitals Cleveland Medical CenterOTHER | 1 | Apr 19, 2022 | clinicaltrials |
| NCT03472833 | High-dose Vitamin D3 in Pancreas Cancer(VITdCUT) | terminated | Phase 3 | 25 | Medical University of GrazOTHER | 1 | Feb 15, 2022 | clinicaltrials |
| NCT04034355 | Preventive Treatment of OxaLiplatin Induced peripherAl neuRopathy in Adjuvant Colorectal Cancer(POLAR-A) | terminated | Phase 3 | 301 | Egetis TherapeuticsINDUSTRY | 10 | Jan 26, 2022 | clinicaltrials |
| NCT03654729 | Preventive Treatment of Oxaliplatin Induced Peripheral Neuropathy in Metastatic Colorectal Cancer (POLAR-M)(POLAR-M) | terminated | Phase 3 | 291 | Egetis TherapeuticsINDUSTRY | 13 | Dec 17, 2021 | clinicaltrials |
| NCT01387932 | HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer(HiQuality) | terminated | Phase 3 | 235 | Merit Medical Systems, Inc.INDUSTRY | 5 | Nov 30, 2021 | clinicaltrials |
| NCT01956812 | Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer(PANCRIT®-1) | terminated | Phase 3 | 334 | Gilead SciencesINDUSTRY | 8 | Aug 16, 2021 | clinicaltrials |
Data updated 19 days agoSource updated Sep 10, 2026source: clinicaltrials